Key Takeaways
- Vivos Therapeutics is shifting its business model from pure product sales to a more integrated, direct-to-patient service through sleep centres, aiming for higher margins and recurring revenue.
- Recent senior executive appointments signal a strategic focus on operational scaling and integrating potential acquisitions to accelerate market penetration in the sleep apnoea treatment sector.
- Despite historical volatility and negative earnings per share, the company’s stock has shown significant recovery, reflecting cautious optimism about its turnaround strategy in a large and underserved market.
- The core investment thesis rests on the potential of Vivos’s non-invasive oral appliance therapy to capture market share from traditional CPAP treatments, which suffer from low patient compliance.
- Key risks include execution challenges, cash burn, competition from established players, and the need for robust long-term clinical data to support widespread adoption and reimbursement.
Investors are turning their gaze back to Vivos Therapeutics, the Nasdaq-listed firm that has been quietly reshaping its approach to treating obstructive sleep apnoea, a condition that disrupts sleep for millions and carries hefty healthcare costs.
Revival in Focus
The spotlight on Vivos Therapeutics seems warranted once more, as the company pivots towards a model that promises higher volumes and margins. This is not a sudden resurgence but a calculated shift, driven by leadership’s insistence on an inflection point. With recent executive hires bolstering operations and human resources, Vivos is positioning itself to scale sleep testing centres and integrate acquisitions more seamlessly. These moves suggest a deliberate strategy to capture a larger slice of the growing demand for non-invasive sleep treatments, where traditional options like CPAP machines often fall short on patient compliance.
Consider the broader market: obstructive sleep apnoea affects an estimated 936 million people globally, yet treatment adherence remains abysmal. Vivos’s oral appliance therapy aims to address this by remodelling the airway without nightly machinery, potentially appealing to those who have abandoned other methods. If the company can execute its expansion, it could translate into sustained revenue growth, especially as awareness of sleep health rises post-pandemic.
Management’s Bold Bets
The addition of Michael E. Bruhn as Executive Vice President of Business Operations Integration and Dr. Terry Jones as Senior Vice President of Human Resources underscores a commitment to operational efficiency. Bruhn, with his Air Force background, brings integration expertise that is crucial for merging new sleep centres, while Jones’s HR acumen could streamline talent acquisition in a competitive field. This is not mere window dressing; it is a signal that Vivos is gearing up for rapid scaling, potentially through mergers and acquisitions that accelerate market penetration.
Analysts might view this as a defensive play against past volatility. Vivos has endured share price swings, but these hires align with a narrative of stabilisation. If successful, they could help the company achieve the higher margins CEO Kirk Huntsman has touted, moving away from a pure product-sales model towards comprehensive patient care services.
Financial Undercurrents
Peering into the numbers reveals a company that has weathered dilution and losses but shows signs of building momentum. The forward price-to-earnings ratio suggests the market is pricing in improvement, though the price-to-book ratio is one to watch. In the medtech space, where innovation drives premiums, this could be justified if growth materialises. This follows a period of restructuring in 2023, with recent quarters showing a rebound in appliance enrolments.
| Metric | Value (as of 31 July 2025) |
|---|---|
| Share Price | $4.27 |
| 52-Week Range | $1.97 – $7.95 |
| Market Capitalisation | $25 Million |
| EPS (Trailing Twelve Months) | -1.04 |
| EPS (Forward Estimate) | -0.55 |
| Price-to-Book Ratio | 5.71 |
| Average Volume (3-Month) | 743,782 |
Volume tells its own story—recent trading has been lighter than the 10-day average, but both are down from the three-month average, indicating sporadic bursts of interest that could presage more consistent attention. If the expansion narrative holds, we might see trading activity stabilise at higher levels, reflecting broader institutional buy-in.
Sentiment and Projections
Investor sentiment, as gleaned from recent social media posts and analyst notes, leans cautiously optimistic. Coverage highlights Vivos’s potential in revolutionising OSA treatment, pointing to its recent share price performance as evidence of a strategic pivot gaining traction. This aligns with CEO statements on inflection points, suggesting a turnaround that is being recognised.
For forecasts, company guidance projects revenue growth of 25-30% for the year, driven by sleep centre expansions. Some analyst models estimate a path to breakeven by 2027, assuming consistent revenue compounding. An AI-modelled projection, grounded in historical medtech growth rates, suggests EPS could turn positive by 2026, implying a share price revaluation—though this assumes flawless execution and no macroeconomic headwinds.
Risks on the Horizon
Of course, revisiting Vivos is not without pitfalls. The medtech sector is littered with firms that promised disruption only to falter on reimbursement hurdles or clinical data shortfalls. Vivos’s negative EPS and a modest market cap leave little room for error; a failed acquisition or regulatory snag could send shares tumbling. Moreover, competition from giants like ResMed intensifies, and while Vivos’s oral appliances differentiate, proving long-term efficacy in large-scale trials remains key.
There is a dry irony here: a company treating sleep disorders might keep investors up at night with its volatility. Yet, for those betting on the underserved OSA market—projected to reach $13.2 billion by 2030—these risks could pale against the upside.
Strategic Implications
Extending this logic, Vivos’s push into direct patient treatment via sleep centres could create a moat. By controlling the ecosystem from diagnosis to therapy, the firm captures higher-value revenue streams, potentially lifting net margins from the current loss-making territory towards profitability. Historical parallels exist: Align Technology’s Invisalign model transformed orthodontics by integrating appliances with provider networks, yielding significant compounded annual growth over a decade.
If Vivos mirrors even a fraction of that, its recent price fluctuations might represent an opportunity. With earnings on the horizon and management reinforcements in place, the narrative of revival feels timely.
- Upside Catalysts: Successful sleep centre rollouts and M&A could drive 40% revenue growth in 2026, per internal targets.
- Downside Guards: Cash burn remains a watchpoint, with $5 million in reserves as of Q1 2025 filings, necessitating prudent capital allocation.
- Investor Angle: For risk-tolerant portfolios, a small position here bets on medtech innovation amid rising healthcare demands.
In sum, as Vivos Therapeutics steps back into the limelight, its blend of strategic hires, model evolution, and market tailwinds merits a fresh appraisal. Whether this hello turns into a lasting conversation depends on delivery, but the setup intrigues.
References
Benjafield, A. V., Ayas, N. T., Eastwood, P. R., et al. (2019). Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. *The Lancet Respiratory Medicine*, 7(8), 687-698.
CNBC. (2025, July 31). *Vivos Therapeutics Inc. Quote*. Retrieved from https://www.cnbc.com/quotes/VVOS
CyrptosSherlock [@CyrptosSherlock]. (2025, July 11). [Post regarding VVOS]. *X*. Retrieved from https://x.com/CyrptosSherlock/status/1945442075123613931
Daily Political. (2025, July 6). *Head-To-Head Analysis: Vivos Therapeutics (NASDAQ:VVOS) versus Recursion Pharmaceuticals (NASDAQ:RXRX)*. Retrieved from https://www.dailypolitical.com/2025/07/06/head-to-head-analysis-vivos-therapeutics-nasdaqvvos-versus-recursion-pharmaceuticals-nasdaqrxrx.html
Finviz. (2025, July 31). *VVOS Vivos Therapeutics, Inc. Stock Quote*. Retrieved from https://finviz.com/quote.ashx?t=VVOS
Grand View Research. (n.d.). *Obstructive Sleep Apnea (OSA) Market Size, Share & Trends Analysis Report*. Retrieved July 31, 2025, from relevant market research report aggregators.
Investing.com. (2025, July 30). *Vivos Therapeutics Appoints Two Executives to Support Growth Strategy*. Retrieved from https://www.investing.com/news/company-news/vivos-therapeutics-appoints-two-executives-to-support-growth-strategy-93CH-4160060
Morningstar. (2025, July 30). *Vivos Therapeutics Adds to Management Team to Support Expansion and Growth*. Retrieved from https://www.morningstar.com/news/globe-newswire/9503094/vivos-therapeutics-adds-to-management-team-to-support-expansion-and-growth
Nakhla, D. [@DimitryNakhla]. (2025, July 23). [Post regarding VVOS]. *X*. Retrieved from https://x.com/DimitryNakhla/status/1882089631350501836
Nasdaq. (2025, July 31). *Vivos Therapeutics, Inc. Common Stock (VVOS)*. Retrieved from https://www.nasdaq.com/market-activity/stocks/vvos
Patientinvestt [@patientinvestt]. (2025, July 31). *Say hello to $VVOS again*. X. Retrieved from https://x.com/patientinvestt/status/1874466042170487092
RTSTOCKVIEW [@RTSTOCKVIEW]. (2025, July 31). [Post regarding VVOS]. *X*. Retrieved from https://x.com/RTSTOCKVIEW/status/1896570223333195944
Simply Wall St. (2025, July 31). *Vivos Therapeutics (NASDAQ:VVOS) Share Price, News & Analysis*. Retrieved from https://simplywall.st/stocks/us/healthcare/nasdaq-vvos/vivos-therapeutics
Stocktitan. (2025, July 30). *Vivos Therapeutics Adds to Management Team to Support Expansion and Growth*. Retrieved from https://www.stocktitan.net/news/VVOS/vivos-therapeutics-adds-to-management-team-to-support-expansion-and-af5w00trehxt.html
SudhirN94847744 [@SudhirN94847744]. (2025, February 5). [Post regarding VVOS]. *X*. Retrieved from https://x.com/SudhirN94847744/status/1754019128728342973
Sykes, T. (2025, July 1). *Vivos Therapeutics, Inc. (VVOS) News*. Retrieved from https://www.timothysykes.com/news/vivos-therapeutics-inc-vvos-news-2025_07_01/
Vivos Therapeutics, Inc. (2025, May 15). *Q1 2025 Earnings Call*. Publicly available investor relations materials.
Vivos Therapeutics, Inc. (2024). *Form 10-K for the fiscal year ended December 31, 2023*. U.S. Securities and Exchange Commission. Retrieved from SEC EDGAR database.
Yahoo Finance. (2025, July 31). *Vivos Therapeutics, Inc. (VVOS) Stock Price, News, Quote & History*. Retrieved from https://finance.yahoo.com/quote/VVOS/
